STRO
Sutro Biopharma, Inc. NASDAQ Listed Sep 27, 2018$29.63
+4.29%
vs $28.41
Mkt Cap $251.8M
52w Low $6.80
66.9% of range
52w High $40.91
50d MA $31.81
200d MA $18.04
P/E (TTM)
-1.3x
EV/EBITDA
—
P/B
—
Debt/Equity
-0.1x
ROE
144.3%
P/FCF
-1.4x
RSI (14)
51.00
ATR (14)
$2.89
Beta
1.31
50d MA
$31.81
200d MA
$18.04
Avg Volume
307.7K
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
111 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -8.16 | -5.29 | +35.2% | 21.33 | +8.8% | +10.5% | -0.3% | +6.0% | -1.9% | -1.4% | — |
| Nov 6, 2025 | AMC | -4.20 | -6.70 | -59.5% | 9.42 | -4.5% | -13.4% | -1.2% | +0.9% | -0.2% | +14.6% | — |
| Aug 7, 2025 | AMC | -0.39 | -0.14 | +64.1% | 8.00 | +0.5% | +0.2% | -3.6% | +1.4% | -1.5% | +1.0% | — |
| May 8, 2025 | AMC | -0.63 | -0.91 | -44.4% | 9.58 | +4.4% | -9.0% | -0.2% | -6.3% | -10.1% | +19.9% | — |
| Mar 13, 2025 | AMC | -0.86 | -0.89 | -3.5% | 12.50 | -20.1% | -35.2% | +15.1% | -3.9% | -8.4% | -3.0% | — |
| Nov 13, 2024 | AMC | -0.74 | -0.59 | +20.3% | 39.60 | -1.8% | -12.9% | -16.2% | -4.8% | -1.8% | -1.1% | — |
| Aug 13, 2024 | AMC | -0.76 | -0.59 | +22.4% | 32.20 | +10.2% | +11.5% | +12.5% | +4.2% | +9.3% | +3.7% | — |
| May 13, 2024 | AMC | -0.92 | -0.95 | -3.3% | 42.30 | -0.2% | +2.6% | -9.4% | +5.6% | -3.4% | +16.7% | — |
| Mar 25, 2024 | AMC | -0.82 | 0.42 | +151.2% | 32.70 | +17.4% | +27.8% | +17.9% | +14.6% | -5.7% | -4.5% | — |
| Nov 13, 2023 | AMC | -0.76 | -0.81 | -6.6% | 20.70 | -0.5% | +14.5% | +3.8% | -4.5% | +14.5% | +3.0% | — |
| Aug 10, 2023 | AMC | -0.73 | -0.64 | +12.3% | 43.40 | -2.8% | -1.8% | +0.7% | -0.5% | -6.1% | +5.0% | — |
| May 15, 2023 | AMC | -0.83 | -0.76 | +8.4% | 58.80 | -3.9% | -2.6% | +0.3% | -8.0% | +2.3% | -1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 11 | Truist | Reiterates | Buy | $50 | $26.09 | $26.40 | +1.2% | +1.5% | +8.8% | +4.9% | -6.7% | +0.9% |
| May 28 | Barclays | Initiates | Overweight | $56 | $29.69 | $29.99 | +1.0% | -0.2% | -1.4% | -3.4% | -13.5% | +11.3% |
| May 15 | Wedbush | Upgrade | Neutral → Outperform | $60 | $38.42 | $43.85 | +14.1% | +1.4% | -11.5% | -8.1% | -1.7% | -1.6% |
| Apr 30 | Mizuho | Initiates | Outperform | $50 | $35.39 | $36.54 | +3.2% | +3.5% | -2.8% | +7.9% | -2.8% | +1.0% |
| Apr 23 | Citizens | Maintains | Market Outperform → Market Outperform | — | $35.53 | $35.93 | +1.1% | -2.0% | -4.3% | +0.8% | +3.3% | +2.0% |
| Apr 17 | Citizens | Maintains | Market Outperform → Market Outperform | — | $29.35 | $30.57 | +4.2% | +7.5% | +9.6% | -0.7% | +3.4% | -2.0% |
| Mar 25 | Deutsche Bank | Maintains | Buy → Buy | — | $23.57 | $24.38 | +3.4% | -0.3% | +6.0% | -1.9% | -1.4% | +3.4% |
| Mar 24 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $21.33 | $23.21 | +8.8% | +10.5% | -0.3% | +6.0% | -1.9% | -1.4% |
| Mar 24 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $21.33 | $23.21 | +8.8% | +10.5% | -0.3% | +6.0% | -1.9% | -1.4% |
| Jan 20 | Citizens | Upgrade | Market Perform → Market Outperform | — | $13.82 | $14.19 | +2.7% | +8.0% | +5.9% | +3.3% | -7.8% | +3.9% |
| Dec 22 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.98 | $9.83 | -1.5% | +3.9% | +0.1% | +3.6% | +6.9% | -3.4% |
| Aug 12 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $7.73 | $7.65 | -1.0% | +1.4% | -1.5% | +1.0% | +12.6% | +4.2% |
| Jun 16 | Piper Sandler | Upgrade | Neutral → Overweight | — | $7.99 | $8.70 | +8.9% | +10.3% | -10.3% | +0.5% | +0.9% | -0.2% |
| May 19 | BofA Securities | Maintains | Underperform → Underperform | — | $9.12 | $9.09 | -0.3% | -3.7% | +2.5% | -6.9% | +7.8% | +1.9% |
| Apr 29 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.97 | $8.70 | -3.0% | -2.5% | +20.0% | +1.9% | +2.8% | -4.5% |
| Mar 17 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $8.10 | $8.17 | +0.9% | +15.1% | -3.9% | -8.4% | -3.0% | -3.6% |
| Mar 14 | Wedbush | Downgrade | Outperform → Neutral | — | $12.50 | $9.99 | -20.1% | -35.2% | +15.1% | -3.9% | -8.4% | -3.0% |
| Mar 14 | Citizens Capital Markets | Downgrade | Market Outperform → Market Perform | — | $12.50 | $9.99 | -20.1% | -35.2% | +15.1% | -3.9% | -8.4% | -3.0% |
| Mar 14 | BofA Securities | Downgrade | Buy → Underperform | — | $12.50 | $9.99 | -20.1% | -35.2% | +15.1% | -3.9% | -8.4% | -3.0% |
| Dec 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $23.50 | $23.80 | +1.3% | +4.3% | -10.2% | -3.6% | -2.4% | +1.0% |
| Dec 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $23.50 | $23.80 | +1.3% | +4.3% | -10.2% | -3.6% | -2.4% | +1.0% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.90 | $29.10 | +0.7% | -4.8% | -1.8% | -1.1% | -5.2% | -0.8% |
| Oct 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $33.10 | $33.50 | +1.2% | +14.5% | +1.1% | +0.0% | -1.6% | -1.6% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.10 | $33.50 | +1.2% | +14.5% | +1.1% | +0.0% | -1.6% | -1.6% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.00 | $44.60 | -0.9% | -17.8% | +8.4% | -1.5% | -0.8% | -3.8% |
| Sep 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $45.00 | $44.60 | -0.9% | -17.8% | +8.4% | -1.5% | -0.8% | -3.8% |
| Aug 16 | Truist | Maintains | Buy → Buy | — | $40.40 | $40.40 | +0.0% | +4.2% | +9.3% | +3.7% | -4.4% | -0.2% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.20 | $35.50 | +10.2% | +11.5% | +12.5% | +4.2% | +9.3% | +3.7% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $43.40 | $43.40 | +0.0% | -9.4% | +5.6% | -3.4% | +16.7% | -3.0% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.30 | $42.20 | -0.2% | +2.6% | -9.4% | +5.6% | -3.4% | +16.7% |
| May 14 | Wedbush | Maintains | Outperform → Outperform | — | $42.30 | $42.20 | -0.2% | +2.6% | -9.4% | +5.6% | -3.4% | +16.7% |
| Apr 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $50.90 | $51.90 | +2.0% | +0.0% | -3.3% | -0.8% | -2.9% | -7.4% |
| Apr 3 | Truist | Maintains | Buy → Buy | — | $50.90 | $51.90 | +2.0% | +0.0% | -3.3% | -0.8% | -2.9% | -7.4% |
| Apr 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $50.90 | $51.90 | +2.0% | +0.0% | -3.3% | -0.8% | -2.9% | -7.4% |
| Apr 3 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $50.90 | $51.90 | +2.0% | +0.0% | -3.3% | -0.8% | -2.9% | -7.4% |
| Mar 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $49.30 | $49.70 | +0.8% | +14.6% | -5.7% | -4.5% | +0.0% | -3.3% |
| Mar 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $41.80 | $42.60 | +1.9% | +17.9% | +14.6% | -5.7% | -4.5% | +0.0% |
| Mar 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $32.70 | $38.40 | +17.4% | +27.8% | +17.9% | +14.6% | -5.7% | -4.5% |
| Mar 26 | Wedbush | Maintains | Outperform → Outperform | — | $32.70 | $38.40 | +17.4% | +27.8% | +17.9% | +14.6% | -5.7% | -4.5% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.70 | $38.40 | +17.4% | +27.8% | +17.9% | +14.6% | -5.7% | -4.5% |
| Nov 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $23.70 | $23.40 | -1.3% | +3.8% | -4.5% | +14.5% | +3.0% | -2.9% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.70 | $20.60 | -0.5% | +14.5% | +3.8% | -4.5% | +14.5% | +3.0% |
| Oct 23 | Wedbush | Maintains | Outperform → Outperform | — | $31.90 | $31.90 | +0.0% | -7.5% | -5.8% | +1.4% | -3.5% | -5.9% |
| Sep 6 | Truist | Maintains | Buy → Buy | — | $44.00 | $44.00 | +0.0% | +2.7% | +0.4% | -0.4% | +1.8% | -1.3% |
| Aug 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $42.60 | $42.10 | -1.2% | +0.7% | -0.5% | -6.1% | +5.0% | +6.2% |
| Aug 11 | Wedbush | Maintains | Outperform → Outperform | — | $43.40 | $42.20 | -2.8% | -1.8% | +0.7% | -0.5% | -6.1% | +5.0% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.40 | $42.20 | -2.8% | -1.8% | +0.7% | -0.5% | -6.1% | +5.0% |
| Jun 27 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $52.50 | $52.60 | +0.2% | -3.0% | -2.1% | -6.7% | +0.0% | +0.6% |
| May 17 | JMP Securities | Maintains | Market Outperform → Outperform | — | $57.30 | $57.10 | -0.3% | +0.3% | -8.0% | +2.3% | -1.8% | -0.4% |
| May 17 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $57.30 | $57.10 | -0.3% | +0.3% | -8.0% | +2.3% | -1.8% | -0.4% |
No insider trades available.
8-K · 2.02
!! High
Sutro Biopharma, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 1.02
!! High
Unknown — 8-K 1.02: Material Agreement Terminated
The termination of a material agreement signals potential operational disruption or loss of revenue/partnership benefits, requiring investors to assess impact on earnings guidance and competitive positioning.
Mar 23
8-K
Sutro Biopharma, Inc. -- 8-K Filing
Sutro Biopharma secured funding through an offering to support R&D, clinical development, manufacturing, and potential acquisitions for its biopharmaceutical pipeline.
Feb 10
Institutional (13F) — Top 4
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Aju Ib Investment Co., Ltd. | 17,500 | $436K | — | Mar 2026 |
| 2 | Fortitude Family Office, Llc | 56 | $1K | — | Mar 2026 |
| 3 | Eversource Wealth Advisors, Llc | 64 | $856 | Added | Mar 2026 |
| 4 | Bogart Wealth, Llc | 50 | $579 | Reduced | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Ultra-Small Company Market Fund | 3,000 | $75K | Mar 2026 |
| 2 | Small Cap Core Fund | 252 | $6K | Mar 2026 |
Valuation
Market Cap
$251.8M
Enterprise Value
$118.3M
P/E (TTM)
-1.32x
Forward P/E
—
PEG Ratio
0.02x
P/B
—
P/S
2.46x
P/FCF
-1.41x
EV/EBITDA
—
Shares Out
8.5M
Financials (TTM)
Revenue
$102.5M
Net Income
-$191.1M
EBITDA
-$97.6M
Free Cash Flow
-$178.9M
Op Cash Flow
-$177.2M
EPS Basic
$-22.49
EPS Diluted
$-22.49
EPS Forward
$-9.05
Gross Margin
92.8%
Op Margin
-102.4%
Net Margin
-186.5%
Balance Sheet
Total Assets
$173.8M
Total Liab.
$306.3M
Total Equity
-$132.5M
Cash
$141.4M
LT Debt
$7.9M
Book Value/Sh
$-15.59
Debt/Equity
-0.12x
Current Ratio
2.01
Quick Ratio
2.01
Returns & Growth
ROE
144.3%
ROA
-109.9%
ROIC
-98.5%
Rev Growth YoY
+65.2%
EPS Growth YoY
+24.0%
Price Returns
2W
-23.9%
1M
-20.2%
3M
+42.8%
6M
+218.1%
12M
+225.5%
Technicals
52W High
$40.91
52W Low
$6.80
50d MA
$31.81
200d MA
$18.04
RSI (14)
51.00
ATR (14)
$2.89
Beta
1.31
Avg Volume
308K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$50.00
High
$50.00
Low
$50.00
Median
$50.00
Data updated apr 27, 2026 3:20am
· Source: financialmodelingprep.com